[1] Wenquan L, Kun D, Jiaqi B, et al.Relationship between uric acid to albumin ratio and in-stent restenosis in patients with coronary artery disease undergoing drug-eluting stenting[J]. Coron Artery Dis, 2023, 34(8):589-594.
[2] 张小聪,邓世昌,黄志石.术前血清肌腱蛋白-C水平与冠心病病人冠状动脉支架植入术后再狭窄的相关性分析[J].安徽医药,2020,24(5):927-930.
[3] Saima M, Gianluca P, Edoardo C, et al.Diagnostic accuracy of subendocardial vs.transmural myocardial perfusion defect for the detection of in-stent restenosis or progression of coronary artery disease after percutaneous coronary intervention[J]. J Cardiovasc Comput Tomogr, 2023, 17(4):277-280.
[4] 中华医学会心血管病学分会介入心脏病学组,中华医学会心血管病学分会动脉粥样硬化与冠心病学组,中国医师协会心血管内科医师分会血栓防治专业委员会,等.稳定性冠心病诊断与治疗指南[J].中华心血管病杂志,2018,46(9):680-694.
[5] Menran R, Dangas G, Abizaid A S, et al.Angiographic patterns of in-stent restenosis:classification and implications for long-term outcome[J]. Circulation, 1999, 100(18):1872-1878.
[6] 黄治霞,许中恒,陶黎.动脉粥样硬化支架植入术后冠状动脉再狭窄的相关危险因素分析[J].中国循证心血管医学杂志,2023,15(7):847-849.
[7] 朱晨玉江,吕湛,朱法胜,等.冠心病患者经皮冠状动脉介入治疗后支架内再狭窄复发的危险因素及预测模型构建研究[J].中国循环杂志,2024,39(5):456-463.
[8] Juan Z, Qian Z, Ke Z, et al.Risk factors for in-stent restenosis after coronary stent implantation in patients with coronary artery disease:a retrospective observational study[J]. Medicine, 2022, 101(47):e31707.
[9] 罗鸿池,马涵英,韩红亚,等.冠心病合并糖尿病患者经皮冠状动脉介入术后支架内再狭窄危险因素的研究进展[J].中国医药,2024,19(5):763-767.
[10] 王佳旺,吴琼,刘莲莲,等.冠心病患者经皮冠状动脉介入术治疗后发生支架内再狭窄的危险因素及预测模型[J].山东医药,2024,64(6):57-60.
[11] Antico S D C R, Rodrigo B, Moreira F R, et al. Carotid artery atherosclerotic profile as risk predictor for restenosis after coronary stenting[J]. Arq Bras Cardiol, 2021, 116(4):727-733.
[12] 陈宁,孙婷,陈明.基因C677T多态性与冠状动脉支架植入术后再狭窄的相关性研究[J].中国循证心血管医学杂志,2021,13(6):734-737.
[13] 杨尚铭,李首才,耿超强,等.经皮冠状动脉介入术后支架内再狭窄的研究进展[J].中西医结合心脑血管病杂志,2023,21(20):3754-3760.
[14] 罗江宾,王天松,何喜民,等.冠心病患者经皮冠状动脉介入治疗术后支架内再狭窄的相关危险因素分析[J].现代生物医学进展,2019,19(15):2966-2969,2983. |
